Net32
Executives
6Board of Directors
1This profile has not been claimed.
Highlight your management team’s expertise.
Net32 Board of Director
1 Board of directors
Net32 has 1 board of directors, including James Healy.
Name | Firm | Work History | Other Seats |
|---|---|---|---|
James Healy | Jim joined Sofinnova in 2000 as a General Partner. Dr. Healy finances companies that are developing potentially important therapies that could be transformative for patients. He has funded companies where eleven products were approved by the FDA or EMA. Eighteen of his investments have gone public and ten have been acquired as private or public companies. He is currently a board observer at Karuna Therapeutics and a member of the board of directors of Ascendis (ASND), Coherus (CHRS), Iterum (ITRM), Natera (NTRA), Nucana (NCNA), Obseva (OBSV) and Y-Mabs (YMAB). Jim received a B.A. in Molecular Biology and B.A. Scandinavian Studies from UC Berkeley where he graduated with Honors and received the Departmental Citation. He subsequently completed the NIH sponsored Medical Scientist Training Program and received his MD and PhD in Immunology from Stanford University where he received the Novartis Foundation Bursary Award and was a Beckman Scholar. He has lectured on entrepreneurship at Stanford University and served on the boards of the Executive Committee at UC Berkeley, the National Venture Capital Association (NVCA) and the Biotechnology Innovation Organization (BIO). | Net32 |
Name | James Healy |
|---|---|
Firm | |
Work History | Jim joined Sofinnova in 2000 as a General Partner. Dr. Healy finances companies that are developing potentially important therapies that could be transformative for patients. He has funded companies where eleven products were approved by the FDA or EMA. Eighteen of his investments have gone public and ten have been acquired as private or public companies. He is currently a board observer at Karuna Therapeutics and a member of the board of directors of Ascendis (ASND), Coherus (CHRS), Iterum (ITRM), Natera (NTRA), Nucana (NCNA), Obseva (OBSV) and Y-Mabs (YMAB). Jim received a B.A. in Molecular Biology and B.A. Scandinavian Studies from UC Berkeley where he graduated with Honors and received the Departmental Citation. He subsequently completed the NIH sponsored Medical Scientist Training Program and received his MD and PhD in Immunology from Stanford University where he received the Novartis Foundation Bursary Award and was a Beckman Scholar. He has lectured on entrepreneurship at Stanford University and served on the boards of the Executive Committee at UC Berkeley, the National Venture Capital Association (NVCA) and the Biotechnology Innovation Organization (BIO). |
Other Seats | Net32 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.